Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium channel protein type 7 subunit alpha (NaV1.7) is a voltage-gated sodium channel predominantly expressed in peripheral neurons, including those in the dental pulp. It plays a central role in the initiation and propagation of action potentials, especially in nociceptors, and is implicated in the pathophysiology of pain, hyperalgesia, and pulpitis. Changes in expression or function of NaV1.7, as well as NaV1.8, drive pain hypersensitivity following injury or inflammation. These channels represent validated therapeutic targets for managing dental pain and related neuropathic pain conditions. Selective inhibitors are in development, aiming to block painful signaling while minimizing systemic effects.
Inhibition of sodium influx, which suppresses action potential propagation and neuronal excitability; Blockade can reduce or eliminate pain signaling from pulp tissue
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium channel protein type 7 subunit alpha (NaV1.7) (NaV1.7).